Symbiotic Capital
Overview
A global life science credit firm that provides lending solutions and non-dilutive capital to support the growth of established, late-stage companies across biotechnology, medical devices, diagnostics, tools, synthetic biology, and other healthcare subsectors. Affiliated with Bellco Capital, the firm was founded by Dr. Arie Belldegrun.
Portfolio Companies
4
Website
symbioticcapital.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| TARGAN | Mar 2026 | Debt | Lead |
| Cleveland Diagnostics | Jan 2024 | Growth Equity | Co-investor |
| Accelus | Jan 2024 | Debt | Lead |
| Caresyntax | Aug 2024 | Debt | - |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Symbiotic Capital based?
Symbiotic Capital is headquartered in Los Angeles, California, United States.
When was Symbiotic Capital founded?
Founding year information for Symbiotic Capital is not publicly available.
How many portfolio companies does Symbiotic Capital have?
Symbiotic Capital has 4 portfolio companies in Caplight's dataset.
What are some companies in Symbiotic Capital's portfolio?
Portfolio companies visible on Caplight include TARGAN, Cleveland Diagnostics, Accelus, Caresyntax.
What was Symbiotic Capital's most recent investment shown here?
Symbiotic Capital's most recent investment in this portfolio sample was in TARGAN in 2026.
What sectors does Symbiotic Capital focus on?
Symbiotic Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Healthcare & Life Sciences, Enterprise Software.
What company stages does Symbiotic Capital focus on?
Symbiotic Capital typically invests at the Late stage.
What is Symbiotic Capital's AUM?
Symbiotic Capital's assets under management are estimated between $600.0M and $600.0M.